← Back to Search

Noninvasive Brain Stimulation

Transcranial Magnetic Stimulation for Cognitive Function

N/A

Recruiting

Led By Derek E Nee, PhD

Research Sponsored by Florida State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, pre-intervention and immediately after intervention

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at how a non-invasive brain stimulation called TMS affects brain regions linked to focus and attention.

Who is the study for?

This trial is for right-handed individuals aged 18-30 who speak English fluently, having learned it by age 6. It's not suitable for those with neurological or psychiatric disorders, pregnant women, people with tinnitus, a family history of epilepsy, or anyone taking pro-epileptic drugs or medications.

What is being tested?

The study is testing the effects of transcranial magnetic stimulation (TMS) on two brain areas: the prefrontal cortex and posterior parietal cortex. TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain.

What are the potential side effects?

Potential side effects of TMS may include discomfort at the site of stimulation, headache, lightheadedness, tingling sensations on the scalp or face during treatment. Serious side effects are rare but can include seizures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, pre-intervention and immediately after intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, pre-intervention and immediately after intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, pre-intervention and immediately after intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in PFC-PPC activation

Change in PFC-PPC effective connectivity

Secondary study objectives

Change in contextual control accuracy

Change in contextual control speed

Change in temporal control accuracy

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: MFG-TMSExperimental Treatment1 Intervention

Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.

Group II: FPl-TMSExperimental Treatment1 Intervention

Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.

Group III: S1-TMSActive Control1 Intervention

Transcranial magnetic stimulation to the primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

transcranial magnetic stimulation

2013

Completed Phase 2

~820

Do I qualify?Apply below to find out